Notes from the India AI Impact Summit 2026

I spent a few days at the India AI Impact Summit 2026 in New Delhi, a gathering centered on People, Planet, and Progress, to gain a firsthand view of India’s AI adoption and the distinctive way the country is shaping and integrating AI. The summit drew many of the biggest names in AI and technology, including Sam Altman, Sundar Pichai, Dario Amodei, Demis Hassabis, Jensen Huang, Brad Smith, Alexandr Wang, and Yann LeCun, alongside global policymakers, researchers, and industry leaders.

The signal underneath the noise

The headline announcements focused on compute and datasets: expanding IndiaAI’s compute capacity on top of an existing GPU base, and continuing to build AIKosh as a national repository for India-centric data and models.

What stood out to me was how the conversation has quietly shifted from “Can we train models?” to “Can we deploy them inside regulated, data-sensitive workflows within a reasonable budget?”

That shift is exactly where biologics operates. Antibody engineering, developability triage, and target-evidence generation are not constrained by the absence of frontier models. They’re constrained by fragmented assay data, weak provenance, and the persistent gap between a notebook output and a decision a program team can confidently operationalize.

Three things that stood out

• Sovereignty is becoming a product requirement. Public research bodies and pharma teams I spoke to were specific about data residency and audit. That favors architectures that keep retrieval and tool-use auditable end-to-end - the kind of thing MCP-style toolchains do well.
• The "Global South stack" framing. the emphasis was less on frontier-model performance and more on reliability, traceability, and deployment economics. Another noticeable shift was the focus on practical, domain-specific AI systems rather than broad general-purpose ones. In markets where budgets, infrastructure, and specialist talent are constrained, lightweight and workflow-native AI tools appear far more compelling than expensive generalized platforms.
• Datasets, not demos, were the most asked-about asset. What also became clear is that datasets are emerging as the durable competitive advantage. Nearly every meaningful conversation eventually converged on the same questions: how data is collected, how it is standardized, who can access it, and whether downstream decisions can be trusted.

What I'm taking back to UniBio Intelligence

Nothing at the summit changed our thesis - it sharpened it. The work we're doing on skills and MCP servers for biomedical datasets and tools, expert-verified outputs, and workflow-grounded agents lines up directly with what we observed here.

If you were at the summit and are thinking about biologics data, drug discovery tooling, or AI agents for translational research, I'd genuinely like to compare notes.

Citing This Work

If you found this post useful or reference these observations in your work, please cite:

@misc{ubi2026indiaaiimpactsummit2026,
  author = {Kohar, Vivek},
  title = {Notes from the India AI Impact Summit 2026},
  year = {2026},
  url = {https://unibiointelligence.com/blog/india-ai-impact-summit-2026},
  note = {Accessed: 2026-05-12}
}

References